CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-10 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −3,026 | $18.00 | $54K | 168,299 |
| 2023-06-29 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise | +8,790 | $2.10 | $18K | 36,747 |
| 2023-06-29 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −8,790 | 74,657 | ||
| 2023-06-22 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −7,097 | $16.02 | $114K | 42,473 |
| 2023-06-21 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise 10b5-1 | +17,500 | $2.10 | $37K | 45,457 |
| 2023-06-21 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −8,593 | $14.84 | $128K | 36,864 |
| 2023-06-21 | WENTWORTH KORY JAMES Chief Financial Officer | Sale 10b5-1 | −8,907 | $15.17 | $135K | 27,957 |
| 2023-06-21 | WENTWORTH KORY JAMES Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,500 | 83,447 | ||
| 2023-06-20 | Dowden Nathan J Chief Operating Officer | Sale 10b5-1 | −8,885 | $14.94 | $133K | 49,570 |
| 2023-06-08 | PARMAR KUSH Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2023-06-08 | Thistle Mary Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2023-06-08 | Crowley John F Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2023-06-08 | KIM PETER S Director | Grant or award · Stock Option (Right to Buy) | +16,000 | 16,000 | ||
| 2023-04-27 | Doshi Dipal President and CEO | Sale 10b5-1 | −2,000 | $13.71 | $27K | 202,069 |
| 2023-04-17 | Doshi Dipal President and CEO | Sale 10b5-1 | −2,092 | $18.01 | $38K | 204,069 |
| 2023-04-17 | Sethuraman Natarajan Chief Scientific Officer | Sale 10b5-1 | −3,961 | $18.00 | $71K | 171,325 |
| 2023-04-04 | Zeiher Bernhardt G Director | Grant or award · Stock Option (Right to Buy) | +32,000 | 32,000 | ||
| 2023-03-27 | Doshi Dipal President and CEO | Sale 10b5-1 | −1,800 | $14.63 | $26K | 256,011 |
| 2023-03-27 | Doshi Dipal President and CEO | Sale 10b5-1 | −200 | $15.51 | $3K | 255,811 |
| 2023-03-02 | WENTWORTH KORY JAMES Chief Financial Officer | Shares withheld for taxes | −1,005 | $11.60 | $12K | 43,904 |
Page 16 of 26 · 517 trades